Amorepacific Corporation (090430) Fair Value & Analysis
Consumer Defensive · KR · Market cap 7.4T KRW
Analysis
Amorepacific Corporation (090430) currently trades at 96,200 KRW, while our model-based Fair Value estimate is 84,785 KRW — implying the stock looks roughly 11.9% overvalued today. We read business quality at 94/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Amorepacific Corporation researches, develops, manufactures, markets, sells, and trades cosmetics and beauty products worldwide. It offers cosmetics under the Sulwhasoo, Laneige, Innisfree, AP Beauty, Hera, Primera, Iope, Mamonde, Hanyul, espoir, Etude, Odyssey, Be Ready, Holitual, Tata Harper, and Cosrx brands; medical beauty products under the Aestura brand; beauty devices under the maekON brand; and inner beauty products under the VitalBeautie brand. The company also provides hair beauty products under the Ryo, Mise-en-Scène, Labo-H, Ayunche, Amos Professional, and Longtake brands; body care products under the Illiyoon, Hapy Bath, and Skin U brands; dental care products under the Median and Gentist brands; and tea products under the Osulloc brand. In addition, it engages in the manufacture and sale of detergent, and organic and inorganic compounds; manufacture, processing, and trade of food and other products; product packaging and facility management; and equipment design and pr…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.